Clinical trials: Facial Skin
Acne Vulgaris
Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris
The purpose of this study is to compare the effectiveness of two marketed products in subjects with facial acne vulgaris
- Trial name
- NCT00757523
- Testing
- Epiduo Gel, Duac Gel
- Where
- 17 sites in Germany
- Volunteers
- 382 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Open, prospective, randomized, single-centre study in patients with moderate to severe facial acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4 inflammatory lesions, will be selected in…
- Trial name
- NCT01160848
- Testing
- Area cleaned with saline water and occluded with Tegaderm, Area cleaned with saline water, Area cleaned with Ethyl alcohol solution
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Photocure
Acne Vulgaris
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
- Trial name
- NCT03915860
- Testing
- Trifarotene
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Galderma R&D
Acne Vulgaris
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.
- Trial name
- NCT00525499
- Testing
- ASC-J9 cream
- Where
- 10 sites in United States
- Volunteers
- 186 people
- Sponsor
- AndroScience Corp
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
- Trial name
- NCT01017146
- Testing
- Tazarotene foam, Vehicle Foam
- Where
- 22 sites in United States, Canada
- Volunteers
- 744 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
- Trial name
- NCT01628549
- Testing
- 50 mg P005672-HCl, 100 mg P005672-HCl
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608476
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 52 sites in United States, Bulgaria and 4 more
- Volunteers
- 732 people
- Sponsor
- Cassiopea SpA
Acne Vulgaris
A Study of a Laser for the Treatment of Acne Vulgaris
The purpose of this study is to evaluate the onset, duration, efficacy and safety of the laser for the treatment of acne vulgaris.
- Trial name
- NCT05430464
- Testing
- 1726nm Laser System
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Cutera Inc.
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Acne Vulgaris
Treatment of Moderate to Severe Facial Acne Vulgaris
Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and…
- Trial name
- NCT00612573
- Testing
- Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Warner Chilcott
Atopic Dermatitis
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
This study is not being conducted in the United States of America (USA). Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching).
- Trial name
- NCT00130364
- Testing
- Pimecrolimus
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Acne Vulgaris
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
- Trial name
- NCT02189629
- Testing
- CD5789 (trifarotene)
- Where
- 32 sites in United States, Czechia and 2 more
- Volunteers
- 453 people
- Sponsor
- Galderma R&D
Acne
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
The aim of this study is to evaluate the efficacy of the RV3278B-OS0386 cosmetic product, compared to the control product in managing acne relapse during the 12-month maintenance phase follow-up after oral isotretinoin treatment…
- Trial name
- NCT07341659
- Testing
- Test product RV3278BB-OS0386, Control product RV3278B-OS0548
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 102 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Acne Vulgaris
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or…
- Trial name
- NCT02524665
- Testing
- MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- Volunteers
- 20 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
The objective of the study is to compare the safety and efficacy of multiple formulations of BLI1100 to a control group and placebo in treating patients with moderate-severe acne vulgaris.
- Trial name
- NCT02604680
- Testing
- BLI1100-1, BLI1100-2, BLI1100-3
- Where
- 50 sites in United States
- Volunteers
- 509 people
- Sponsor
- Braintree Laboratories
Acne
Topical ASC-J9 Cream for Acne
To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.
- Trial name
- NCT01289574
- Testing
- ASC-J9
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 181 people
- Sponsor
- AndroScience Corp
Acne Vulgaris
DUAC® Early Onset Efficacy Study in Japanese Subjects
This is a multicentre, randomized, single-blind (investigator is blinded), active (the combination therapy of adapalene [ADA] and clindamycin [CLDM])-controlled and parallel-group study in Japanese subjects with facial acne…
- Trial name
- NCT02557399
- Testing
- Duac® fixed dose combination gel, ADA 0.1% gel, CLDM 1% gel
- Where
- 15 sites in Japan
- Volunteers
- 350 people
- Sponsor
- GlaxoSmithKline
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to…
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Trial name
- IOLITE (NCT07016750)
- Testing
- KB803
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Krystal Biotech, Inc.
Acne
Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage
This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.
- Trial name
- NCT03009903
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MBcure Ltd
Acne Vulgaris
A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash
The purpose of this study is to evaluate the tolerability of a combined regimen of a topical antibiotic and retinoid and a benzoyl peroxide wash.
- Trial name
- NCT00891982
- Testing
- CTGel/ BPO Wash, Soap Free Cleanser and CTGel
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stiefel, a GSK Company